European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Approval Based on Updated Positive Overall Survival Results from the Phase 3 ECHELON-1 Study for…